• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    $5M Bet On This Biotechnology Stock? Check Out These 3 Stocks Insiders Are Buying

    7/5/23 8:53:02 AM ET
    $BDTX
    $HCSG
    $NHC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Hospital/Nursing Management
    Health Care
    Get the next $BDTX alert in real time by email

    Although US stocks closed slightly higher on Monday, there were a few notable insider trades.

    When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

    Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.

    Black Diamond Therapeutics

    • The Trade: Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) 10% owner BB Biotech AG acquired a total of 1,000,000 shares an average price of $5.00. To acquire these shares, it cost around $5 million.
    • What’s Happening: Stifel upgraded Black Diamond Therapeutics from Hold to Buy and raised the price target from $2 to $10.
    • What Black Diamond Therapeutics Does: Black Diamond Therapeutics Inc is a precision oncology medicine company.

    National HealthCare

    • The Trade: National HealthCare Corporation (NYSE:NHC) Director Richard F. Laroche Jr. acquired a total of 2,100 shares at an average price of $61.40. To acquire these shares, it cost around $128,944.
    • What’s Happening: - -National HealthCare reported net operating revenues and grant income for the quarter ended March 31, 2023 totaled $269,563,000, up from $278,983,000 for the quarter ended March 31, 2022.
    • What National HealthCare Does: National Healthcare Corp Provides long-term care facilities. Its principal business includes the operation of skilled nursing facilities, assisted living facilities, independent living facilities, and home care programs.

    Don’t forget to check out our premarket coverage here

    Healthcare Services Group

    • The Trade: Healthcare Services Group, Inc. (NASDAQ:HCSG) Director Kurt Simmons Jr bought a total of 1,005 shares at an average price of $14.93. To acquire these shares, it cost around $15,005.
    • What’s Happening: Healthcare Services Group reported revenue of $417.2 million for the three months ended March 31, 2023.
    • What Healthcare Services Group Does: Healthcare Services Group Inc is a provider of housekeeping and facility management services to the healthcare industry.

     

    Check This Out: Investor Sentiment Declines Ahead Of Fed Minutes

    Get the next $BDTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BDTX
    $HCSG
    $NHC

    CompanyDatePrice TargetRatingAnalyst
    Healthcare Services Group Inc.
    $HCSG
    3/3/2026$22.00Sector Perform
    RBC Capital Mkts
    Healthcare Services Group Inc.
    $HCSG
    2/20/2026Mkt Perform → Outperform
    William Blair
    Black Diamond Therapeutics Inc.
    $BDTX
    12/3/2025Buy → Neutral
    Guggenheim
    Black Diamond Therapeutics Inc.
    $BDTX
    11/18/2025$9.00Overweight
    Piper Sandler
    Healthcare Services Group Inc.
    $HCSG
    11/13/2025$20.00Market Perform
    BMO Capital Markets
    Black Diamond Therapeutics Inc.
    $BDTX
    10/16/2025$8.00Buy
    Stifel
    Black Diamond Therapeutics Inc.
    $BDTX
    9/4/2025$8.00Buy
    Guggenheim
    Healthcare Services Group Inc.
    $HCSG
    7/29/2025$16.00Neutral → Outperform
    Macquarie
    More analyst ratings

    $BDTX
    $HCSG
    $NHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on Healthcare Services Group with a new price target

    RBC Capital Mkts initiated coverage of Healthcare Services Group with a rating of Sector Perform and set a new price target of $22.00

    3/3/26 8:27:50 AM ET
    $HCSG
    Hospital/Nursing Management
    Health Care

    Healthcare Services Group upgraded by William Blair

    William Blair upgraded Healthcare Services Group from Mkt Perform to Outperform

    2/20/26 8:19:55 AM ET
    $HCSG
    Hospital/Nursing Management
    Health Care

    Black Diamond Therapeutics downgraded by Guggenheim

    Guggenheim downgraded Black Diamond Therapeutics from Buy to Neutral

    12/3/25 12:43:23 PM ET
    $BDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BDTX
    $HCSG
    $NHC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

    Clinical update on track for Q2 2026 for Phase 2 trial of silevertinib in patients with non-classical EGFRm NSCLC, including preliminary DOR and PFS data in frontline settingCompany is preparing to initiate a randomized Phase 2 trial of silevertinib in patients with newly diagnosed EGFR altered GBM in Q2 2026 Cash, cash equivalents, and investments of $128.7 million as of December 31, 2025, expected to be sufficient to fund operations into 2H of 2028 CAMBRIDGE, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today r

    3/16/26 4:01:00 PM ET
    $BDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

    CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D. and Chief Scientific Officer Elizabeth Buck, Ph.D., are as follows: 46th Annual TD Cowen Healthcare Conference presentation at 1:10pm ET on Wednesday, March 4, 202625th Annual Needham Virtual Healthcare Conference presentation at 3:00pm ET on Wednesday, April 15, 2026 Webcasts will be available at the

    3/2/26 4:01:00 PM ET
    $BDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    NHC Reports 2025 Year End Earnings

    National HealthCare Corporation (NYSE American: NHC), the nation's oldest publicly traded senior health care company, announced today net operating revenues and grant income for the year ended December 31, 2025 totaled $1,517,781,000 compared to $1,307,382,000 for the year ended December 31, 2024, an increase of 16.1%. The increase in net operating revenues for the 2025 year compared to the 2024 year was due to an 8.4% increase in same-facility net operating revenues, as well as the August 1, 2024 acquisition of White Oak Manor ("White Oak"). The White Oak operations consist of 22 healthcare operations, which includes 15 skilled nursing facilities, two assisted living facilities, four indep

    2/26/26 5:30:00 PM ET
    $NHC
    Hospital/Nursing Management
    Health Care

    $BDTX
    $HCSG
    $NHC
    SEC Filings

    View All

    SEC Form DEF 14A filed by National HealthCare Corporation

    DEF 14A - NATIONAL HEALTHCARE CORP (0001047335) (Filer)

    4/2/26 4:31:31 PM ET
    $NHC
    Hospital/Nursing Management
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by National HealthCare Corporation

    SCHEDULE 13G/A - NATIONAL HEALTHCARE CORP (0001047335) (Subject)

    3/27/26 10:50:18 AM ET
    $NHC
    Hospital/Nursing Management
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Healthcare Services Group Inc.

    SCHEDULE 13G/A - HEALTHCARE SERVICES GROUP INC (0000731012) (Subject)

    3/27/26 9:33:39 AM ET
    $HCSG
    Hospital/Nursing Management
    Health Care

    $BDTX
    $HCSG
    $NHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Simmons Kurt Jr

    4 - HEALTHCARE SERVICES GROUP INC (0000731012) (Issuer)

    4/2/26 4:30:37 PM ET
    $HCSG
    Hospital/Nursing Management
    Health Care

    SEC Form 4 filed by Whalen Thomas Gerard

    4 - HEALTHCARE SERVICES GROUP INC (0000731012) (Issuer)

    4/2/26 4:29:42 PM ET
    $HCSG
    Hospital/Nursing Management
    Health Care

    SEC Form 4 filed by Grant Laura K

    4 - HEALTHCARE SERVICES GROUP INC (0000731012) (Issuer)

    4/2/26 4:28:47 PM ET
    $HCSG
    Hospital/Nursing Management
    Health Care

    $BDTX
    $HCSG
    $NHC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Biotech Growth N V bought $934,080 worth of shares (400,000 units at $2.34), increasing direct ownership by 5% to 8,517,839 units (SEC Form 4)

    4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)

    10/19/23 3:08:35 PM ET
    $BDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BDTX
    $HCSG
    $NHC
    Leadership Updates

    Live Leadership Updates

    View All

    NHC Announces W. Andrew Adams Retirement from NHC Board of Directors

    National HealthCare Corporation (NYSE:NHC) announces the retirement of W. Andrew "Andy" Adams from the NHC Board of Directors effective after the annual meeting of shareholders on May 8, 2025. The son of NHC founder, Dr. Carl Adams, Andy Adams has had an unparalleled career of service and leadership at NHC. He originally joined NHC in 1972 as an Executive Officer. Andy then served as NHC's President from 1974 to 2004 and as Chief Executive Officer (CEO) from 1981 to 2004. Andy's service on the NHC Board of Directors began in 1974 where he also served as Chairman from 1994 to 2008. Andy had a significant impact on NHC. During his time in leadership, NHC's revenue grew to over $521 million i

    5/8/25 5:11:00 PM ET
    $NHC
    Hospital/Nursing Management
    Health Care

    HCSG Announces Appointment of Chief Financial Officer

    Healthcare Services Group, Inc. (NASDAQ:HCSG) today announced the appointment of Vikas Singh as EVP & Chief Financial Officer, effective September 3, 2024. He will oversee HCSG's accounting and finance operations, and play a key role in corporate development, investor relations, and the success of its long-term growth strategy. Mr. Singh brings over two decades of diverse experience in finance, strategy and operations to the Company. Most recently, he served as Managing Director of Leveraged Finance & Capital Markets at Bank of America Securities. Prior to that he worked in the Financial Sponsors Group at Credit Suisse and in the Asia-Pacific Credit Card Group at Citibank. Mr. Singh began

    9/9/24 12:00:00 PM ET
    $HCSG
    Hospital/Nursing Management
    Health Care

    Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors

    SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced the appointment of David M. Epstein, Ph.D., to Gyre's Board of Directors (the "Board"), effective August 6, 2024. Dr. Epstein will serve as a member of the Audit Committee of the Board and as member of the Compensation Committee of the Board. "We are thrilled to welcome David to the Gyre Board," said Han Ying, Ph.D., Chief Executive Officer of Gyre Therapeutics. "His extensive global experience in biotech companies across the U.S. and Asia will be

    8/8/24 4:05:00 PM ET
    $BDTX
    $GYRE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $BDTX
    $HCSG
    $NHC
    Financials

    Live finance-specific insights

    View All

    NHC Reports 2025 Year End Earnings

    National HealthCare Corporation (NYSE American: NHC), the nation's oldest publicly traded senior health care company, announced today net operating revenues and grant income for the year ended December 31, 2025 totaled $1,517,781,000 compared to $1,307,382,000 for the year ended December 31, 2024, an increase of 16.1%. The increase in net operating revenues for the 2025 year compared to the 2024 year was due to an 8.4% increase in same-facility net operating revenues, as well as the August 1, 2024 acquisition of White Oak Manor ("White Oak"). The White Oak operations consist of 22 healthcare operations, which includes 15 skilled nursing facilities, two assisted living facilities, four indep

    2/26/26 5:30:00 PM ET
    $NHC
    Hospital/Nursing Management
    Health Care

    NHC Announces Common Dividend

    National HealthCare Corporation (NYSE:NHC), the nation's oldest publicly traded long-term health care company, announced today that it will pay a quarterly dividend of 64 cents per common share to shareholders of record on March 31, 2026 and payable on April 30, 2026. Forward-Looking Statements Statements in this press release that are not historical facts are forward-looking statements. NHC cautions investors that any forward-looking statements made involve risks and uncertainties and are not guarantees of future performance. The risks and uncertainties are detailed from time to time in reports filed by NHC with the S.E.C., including Forms 8-K, 10-Q and 10-K, and include, among others,

    2/13/26 7:00:00 AM ET
    $NHC
    Hospital/Nursing Management
    Health Care

    Healthcare Services Group Reports Full Year and Fourth Quarter Results

    Exceeds 2025 Expectations Announces New Share Repurchase Program Provides 2026 Growth Outlook Revenue: $1.84 billion for the year (+7.1%) and $466.7 million for the quarter (+6.6%). Net income and EPS: $59.1 million or $0.81 for the year and $31.2 million or $0.44 for the quarter. Cash flow from operations: $145.0 million for the year and $17.4 million for the quarter. Excluding change in payroll accrual, $164.1 million for the year and $36.4 million for the quarter. Share repurchase: Completes $50.0 million buyback and authorizes new $75.0 million, 12-month program. 2026 outlook: Expects mid-single-digit revenue growth. Healthcare Services Group, Inc. (NASDAQ:HCSG) to

    2/11/26 7:00:00 AM ET
    $HCSG
    Hospital/Nursing Management
    Health Care

    $BDTX
    $HCSG
    $NHC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Black Diamond Therapeutics Inc.

    SC 13G/A - Black Diamond Therapeutics, Inc. (0001701541) (Subject)

    11/14/24 1:28:32 PM ET
    $BDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Black Diamond Therapeutics Inc.

    SC 13G - Black Diamond Therapeutics, Inc. (0001701541) (Subject)

    11/14/24 12:02:05 PM ET
    $BDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Healthcare Services Group Inc.

    SC 13G/A - HEALTHCARE SERVICES GROUP INC (0000731012) (Subject)

    11/13/24 5:15:34 PM ET
    $HCSG
    Hospital/Nursing Management
    Health Care